论文部分内容阅读
目的:观察布地奈德雾化吸入治疗慢性阻塞性肺疾病急性加重期(AECOPD)的临床疗效。方法:将94例COPD急性加重期患者随机分为治疗组和对照组各47例,两组均给予常规治疗,同时治疗组给予布地奈德雾化吸入。结果:两组相比,治疗组显效率和总有效率明显优于对照组(P<0.05),而在不良反应方面差异不具有统计学意义(P>0.05)。结论:在常规治疗的基础上,吸入布地奈德辅助治疗副作用小,安全性高,能明显改善患者的临床症状和生活质量,值得推广。
Objective: To observe the clinical efficacy of budesonide inhalation in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: A total of 94 patients with acute exacerbation of COPD were randomly divided into treatment group and control group, 47 cases in each group. Both groups were given routine treatment while budesonide inhalation was given to the treatment group. Results: Compared with the control group, the effective rate and total effective rate of the treatment group were significantly better than those of the control group (P <0.05), but there was no significant difference in adverse reactions (P> 0.05). Conclusion: On the basis of routine treatment, budesonide inhalation with adjuvant therapy has few side effects and high safety. It can significantly improve the clinical symptoms and quality of life of patients and is worthy of promotion.